Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

Prasad, V. K., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 532

Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database

Majhail, N. S., Mau, L., Denzen, E. M., & Arneson, T. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.133 · Cited by 143

Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?

Lamont, E. B., Hayreh, D., Pickett, K. E., Dignam, J. J., List, M. A., Stenson, K. M., Haraf, D. J., Brockstein, B., Sellergren, S. A., & Vokes, E. E. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg035 · Cited by 139

Re: Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?

Munoz, A., & Samet, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh065 · Cited by 112

FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome

Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm574154.htm · Cited by 28

Better by design: What to expect from novel CAR-engineered cell therapies?

Luginbuehl, V., Abraham, E., Kovar, K., Flaaten, R., & Müller, A. M. S. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.107917 · Cited by 29

Cancer Drug Price and Novelty in Mechanism of Action

Miljković, M. D., Tuia, J. E., Olivier, T., Haslam, A., & Prasad, V. K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.47006 · Cited by 26

Expansion processes for cell-based therapies

Scibona, E., & Morbidelli, M. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107455 · Cited by 29

Biomaterials for chimeric antigen receptor T cell engineering

Niu, H., Zhao, P., & Sun, W. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.04.043 · Cited by 28

Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer

Strauss, B. E., Silva, G. R. O., Vieira, I. D. L., Cerqueira, O. L. D., Valle, P. R. D., Medrano, R. F. V., & Mendonça, S. A. (2018) · Clinics · doi:10.6061/clinics/2018/e479s · Cited by 25

Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment

Lin, Y.-T., Chen, Y., Luo, Z., & Wu, Y. (2024) · Nanoscale · doi:10.1039/d3nr05768b · Cited by 27

Effect of graphene oxide on the pH‐responsive drug release from supramolecular hydrogels

Olate‐Moya, F., & Palza, H. (2021) · Journal of Applied Polymer Science · doi:10.1002/app.51420 · Cited by 24

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells

Dezfouli, A. B., Yazdi, M., Benmebarek, M.-R., Schwab, M., Michaelides, S., Micciché, A., Geerts, D., Stangl, S., Klapproth, S., Wagner, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883694 · Cited by 23

Cell-Selective Multifunctional Surface Covalent Reconfiguration Using Aptamer-Enabled Proximity Catalytic Labeling

Guo, Y., Wang, N., Zhong, Y., Li, W., Li, Y., Wang, G., Yao, Y., Shi, Y., Chen, L., Wang, X., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11150 · Cited by 24

Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy

Huang, L., Huang, Z., Zhang, Y., Lin, C., Zhao, Z., Li, R., Saw, P. E., & Xu, X. (2024) · Theranostics · doi:10.7150/thno.93745 · Cited by 24

The design of retroviral vectors used in the CAR‐T products, risk management, and future perspective

Yin, H., & Wei, X. (2025) · MedComm · doi:10.1002/mco2.70067 · Cited by 27

Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer

Mohammadi, M., Akhoundi, M., Malih, S., Mohammadi, A., & Sheykhhasan, M. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2325 · Cited by 24

Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer

Cao, Y., Efetov, S. K., He, M., Fu, Y., Beeraka, N. M., Zhang, J., Zhang, X., Bannimath, N., & Chen, K. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00684-x · Cited by 24

Objectives, benefits and challenges of bioreactor systems for the clinical-scale expansion of T lymphocyte cells

Baudequin, T., Nyland, R., & Ye, H. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107735 · Cited by 22

Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma

Kusowska, A., Kubacz, M., Krawczyk, M., Ślusarczyk, A., Winiarska, M., & Bobrowicz, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031501 · Cited by 22

Estimation of eligibility for and response to CAR-T therapy in the United States

Haslam, A., Høeg, T. B., & Prasad, V. K. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011184 · Cited by 22

Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells

Li, Y.-R., Hu, J., Li, Z., Zhu, E., Chen, Y., Halladay, T., Shen, X., Fang, Y., Zhu, Y., Lyu, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102321 · Cited by 24

Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia

Jaiswal, A. K., Truong, H., Tran, T. M., Lin, T. L., Casero, D., Alberti, M. O., & Rao, D. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-92448-w · Cited by 22

Clinical Translation of Inorganic Nanoparticles and Engineered Living Materials for Cancer Therapy

Gandarias, L., & Faivre, D. (2024) · ChemPlusChem · doi:10.1002/cplu.202400090 · Cited by 19

iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment

Zong, J., & Li, Y.-R. (2025) · Bioengineering · doi:10.3390/bioengineering12010060 · Cited by 20

CAR-T-Cell Therapy: Present Progress and Future strategies

Abbasi, M. H., Riaz, A., Khawar, M. B., Farooq, A., Majid, A., & Sheikh, N. (2022) · Biomedical Research and Therapy · doi:10.15419/bmrat.v9i2.726 · Cited by 18

Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives

Nahm, D. (2023) · Life · doi:10.3390/life13081674 · Cited by 18

Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system

Liu, Y., An, L., Wang, X., Dai, Y., Zhang, C., Wen, Q., & Zhang, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01648-0 · Cited by 14

Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin

Shah, S., Oakes, R. S., & Jewell, C. M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115315 · Cited by 14

Global hotspots and future prospects of chimeric antigen receptor T-cell therapy in cancer research: a bibliometric analysis

Liu, M., Gao, Y., Yuan, Y., Shi, S., Yang, K., Wu, J., Zhang, J., & Tian, J. (2020) · Future Oncology · doi:10.2217/fon-2019-0810 · Cited by 14

How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?

Huguet, M., Raimond, V., Kaltenbach, E., Augusto, V., & Lionel Perrier, A. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.06.005 · Cited by 14

Challenges in the Market Access of Regenerative Medicines, and Implications for Manufacturers and Decision-Makers: A Systematic Review

Qiu, T., Pochopień, M., Hanna, E., Liang, S., Wang, Y., Han, R., Toumi, M., & Aballéa, S. (2022) · Regenerative Medicine · doi:10.2217/rme-2021-0083 · Cited by 14

Catalyst-free thiazolidine formation chemistry enables the facile construction of peptide/protein–cell conjugates (PCCs) at physiological pH

Liu, X., Wang, Y., Ye, B., & Bi, X. (2023) · Chemical Science · doi:10.1039/d3sc01382k · Cited by 14

T-Cell Lymphoma From CAR T-Cell Therapy—A New Safety Notice

Prasad, V. K. (2024) · JAMA · doi:10.1001/jama.2023.27885 · Cited by 13

Defining and Managing High-Priced Cures: Healthcare Payers’ Opinions

Yeung, K., Suh, K., Garrison, L. P., & Carlson, J. J. (2019) · Value in Health · doi:10.1016/j.jval.2018.11.012 · Cited by 13

A disposable impedance-based sensor for in-line cell growth monitoring in CAR-T cell manufacturing

Liu, Z., Jiang, X., Li, S., Chen, J., Jiang, C. H., Wang, K., Zhang, C., & Wang, B. (2023) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2023.108416 · Cited by 13

Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management

Barachini, S., Buda, G., & Petrini, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061574 · Cited by 16

A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin

Chakraborty, A., Onda, M., O’Shea, T., Wei, J., Liu, X., Bera, T. K., & Pastan, I. H. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0233 · Cited by 12

Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies

Srivastava, S., Tyagi, A., Pawar, V. A., Khan, N. H., Arora, K., Verma, C., & Kumar, V. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s474659 · Cited by 12

Dielectrophoretic high-purity isolation of primary T-cells in samples contaminated with leukemia cells, for biomanufacturing of therapeutic CAR T-cells

Ringwelski, B., Jayasooriya, V., & Nawarathna, D. (2020) · Journal of Physics D Applied Physics · doi:10.1088/1361-6463/abc2f3 · Cited by 11

Engineering Platforms for T Cell Modulation

Hickey, J. W., Kosmides, A. K., & Schneck, J. P. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.003 · Cited by 11

Emerging immunological strategies: recent advances and future directions

Zhao, H., Luo, F., Xue, J., Li, S., & Xu, R. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0886-x · Cited by 12

Development of Cell-Carrying Magnetic Microrobots with Bioactive Nanostructured Titanate Surface for Enhanced Cell Adhesion

Li, J., Fan, L., Li, Y., Wei, T., Wang, C., Li, F., Tian, H., & Sun, D. B. (2021) · Micromachines · doi:10.3390/mi12121572 · Cited by 11

MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech

Cioccarelli, C., & Molon, B. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac025 · Cited by 10

The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in the Tumor Microenvironment

Greenshpan, Y., Sharabi, O., Yegodayev, K. M., Novoplansky, O., Elkabets, M., Gazit, R., & Porgador, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137431 · Cited by 13

Healthcare cost and utilization for chimeric antigen receptor ( CAR ) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis

Hoover, A., Reimche, P., Watson, D., Tanner, L. R., Gilchrist, L. S., Finch, M., Messinger, Y. H., & Turcotte, L. M. (2024) · Cancer Reports · doi:10.1002/cnr2.1980 · Cited by 10

Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies

Pochopień, M., Qiu, T., Aballéa, S., Clay, E., & Toumi, M. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1969229 · Cited by 10

Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations

Chabannon, C., & Larghero, J. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.002 · Cited by 10

Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations

Halford, Z., Anderson, M. K., Bennett, L. L., & Moody, J. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020948165 · Cited by 10

Antibody targeted delivery of lipid nanoparticles for RNA therapeutics to immune cells

Kiaie, S. H., Salehi‐Shadkami, H., Sajadi, S. M. S., Gharehchelou, B., & Zangi, A. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145854 · Cited by 11

Cluster of differentiation 19 chimeric antigen receptor T‑cell therapy in pediatric acute lymphoblastic leukemia (Review)

Fu, Z., Zhou, J., Chen, R., Jin, Y.-H., Ni, T., Qian, L.-B., & Xiao, C. (2020) · Oncology Letters · doi:10.3892/ol.2020.11897 · Cited by 10

Co-expressing LRP6 With Anti-CD19 CAR-T Cells for Improved Therapeutic Effect Against B-ALL

He, P., Tan, Z., Wei, Z., Wan, C., & Yang, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01346 · Cited by 9

In silico analysis of a novel protein in CAR T- cell therapy for the treatment of hematologic cancer through molecular modelling, docking, and dynamics approach

Mohanty, R., Manoswini, M., Dhal, A. K., & Ganguly, N. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106285 · Cited by 9

Single-use biosensors for biomanufacturing: Perspective on the state-of-the-art

Hetzler, Z., Lott, N., Poonam, A. D., Dalgan, S., & Wei, Q. (2023) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2023.100512 · Cited by 8

Novel CAR-T cells targeting TRKB for the treatment of solid cancer

Liang, D., Tang, J., Sun, B., He, S., Yang, D., Ma, H., Yun, Y., Zhu, Y., Wei, W., Chen, H., et al. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01936-7 · Cited by 8

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours

Dörr, J., Gregor, L., Lacher, S. B., Öner, A., Sun, Y., Piseddu, I., Fertig, L., Spajic, S., Lesch, S., Michaelides, S., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01610-6 · Cited by 7

The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma

Straßl, I., & Podar, K. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2319672 · Cited by 8

Cancer biotherapy: review and prospect

Liu, Q., & Ma, H. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01376-2 · Cited by 7

Inmunoterapia en cáncer: de los inicios al premio Nobel

Vásquez, L., Castro, D., de León, J., & Beltrán, B. (2020) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2020.371.4329 · Cited by 7

Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art

Peng, B., Jayasinghe, M. K., Le, A. H., Tran, N. M., & Le, M. T. N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.041 · Cited by 7

Antibody-conjugated lipid nanoparticles for in vivo CAR-T cell engineering: From concept to clinical translation

Guo, Z., Zhang, M., & Huang, Y. (2026) · Nano Biomedicine and Engineering · doi:10.1016/j.nbe.2025.100040 · Cited by 7

Adverse Events and Side Effects of Chimeric Antigen Receptor (CAR) T Cell Therapy in Patients with Hematologic Malignancies

Kozani, P. S., & Shabani, S. (2021) · Trends in Medical Sciences · doi:10.5812/tms.116301 · Cited by 6

Progress on Electro‐Enhancement of Cell Manufacturing

Tian, J. S., & Tay, A. K. P. (2023) · Small Methods · doi:10.1002/smtd.202301281 · Cited by 5

Acellular scaffold-based approach for in situ genetic engineering of host T-cells in solid tumor immunotherapy

Dandia, H., Pillai, M. M., Sharma, D., Suvarna, M., Dalal, N., Madhok, A., Ingle, A., Chiplunkar, S. V., Galande, S., & Tayalia, P. (2024) · Military Medical Research · doi:10.1186/s40779-023-00503-6 · Cited by 6

Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches

Digklia, A., Durán, R., Homicskó, K., Kandalaft, L. E., Hocquelet, A., Orcurto, A., Coukos, G., & Denys, A. L. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-2074-1 · Cited by 6

Réglementations applicables aux CAR-T cells : comment les établissements de santé français peuvent-ils s’organiser pour participer à la production et permettre la délivrance de ces immunothérapies innovantes ?

Chabannon, C., & Larghero, J. (2018) · Bulletin du Cancer · doi:10.1016/s0007-4551(19)30050-5 · Cited by 6

Engineering precision therapies: lessons and motivations from the clinic

Xie, M., Viviani, M., & Fussenegger, M. (2020) · Synthetic Biology · doi:10.1093/synbio/ysaa024 · Cited by 6

High throughput screen for the improvement of inducible promoters for tumor microenvironment cues

Sharabi, O., Greenshpan, Y., Ofir, N., Ottolenghi, A., Levi, T., Olender, L., Adler-Agmon, Z., Porgador, A., & Gazit, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-11021-1 · Cited by 6

Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma

Li, Y.-R., DiBernardo, G., Chen, Y., Shen, X., Hon, R., Ruegg, L., Huang, J., Neal, A. S., Moatamed, N. A., Memarzadeh, S., et al. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00746-8 · Cited by 6

Contribution Of Care Source To Cancer Treatment Cost Variation In The US Military Health System

Eaglehouse, Y. L., Aljehani, M. A., Georg, M. W., Castellanos, O. O., Lee, J. S. H., Seabury, S. A., Shriver, C. D., & Zhu, K. (2019) · Health Affairs · doi:10.1377/hlthaff.2019.00283 · Cited by 5

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Hickey, J. W., & Schneck, J. P. (2018) · Journal of Visualized Experiments · doi:10.3791/58640 · Cited by 5

Novel approaches to promote CAR T-cell function in solid tumors

Hull, C., & Maher, J. F. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1614164 · Cited by 5

In vivo CAR-T therapy: from molecular design to precision delivery

Li, H., Wen, W., Zhao, X., & Liang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04232-5 · Cited by 4

Construction of Switch Modules for CAR-T Cell Treatment Using a Site-Specific Conjugation System

Abudureheman, T., Zhou, H., Yang, L., Huang, X.-S., Jing, J.-J., Duan, C., & Chen, K. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00050 · Cited by 4

A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy

Gao, Y., Zhou, Y., He, X., Lin, H., Fang, K., Hou, Q., Wang, H., Zhang, H., Zhang, Y., & Li, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2518634 · Cited by 4

A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma

Cho, J., Jang, S., Kang, D.-W., Lee, E., Koh, H., Yoon, D. H., & Park, M.-H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1282323 · Cited by 4

Scale‐up of the ex vivo expansion of encapsulated primary human T lymphocytes

Kaiser, P., Werner, M., Jérôme, V., & Freitag, R. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26786 · Cited by 4

The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations

Jain, H., Rajendra, A., Sengar, M., Goli, V. B., Thorat, J., Muthuluri, H., Tongaonkar, A. H., Kota, K. K., Gupta, H., Sharma, N., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2093718 · Cited by 4

A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults

Andrade, A. M., Teixeira, V. R., Pogue, R. E., Figueiredo, A. C. M. G., & Carvalho, J. L. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.05.011 · Cited by 4

A calibration-free method for biosensing in cell manufacturing

Chen, J., Liu, Z., Wang, K., Jiang, C., Zhang, C., & Wang, B. (2020) · IISE Transactions · doi:10.1080/24725854.2020.1856982 · Cited by 4

Current Status and Future Development of anti-HIV Chimeric Antigen Receptor T-cell Therapy

Mao, Y., Zhao, C., Zheng, P., Zhang, X., & Xu, J. (2020) · Immunotherapy · doi:10.2217/imt-2020-0199 · Cited by 4

Engineering optimal CAR constructs for allogeneic mesothelin-directed CAR-NKT cells in solid tumor immunotherapy

Li, Y.-R., Zhu, Y., Halladay, T., Shen, X., Yang, Y., Li, Z., Zhu, E., Chen, Y., Huang, J., & Yang, L. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100025 · Cited by 3

Engineering CLL-1 CAR-NK cells via mRNA–LNP for potent antitumor activity and reversal of HLA-E–mediated resistance in acute myeloid leukemia

Shen, J., Peng, J. I. N., Liang, Y., Zhu, J., Xiang, R., Li, Z., Zhu, H., Li, X., Zhang, Y., Wang, W., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03689-4 · Cited by 3

Endosialin-directed CAR-T cell therapy: A promising approach for targeting triple-negative breast cancer

Wali, A. F., Talath, S., Sridhar, S. B., El‐Tanani, M., & Rangraze, I. R. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167852 · Cited by 3

Role of Biomarkers in Personalized Medicine

Islam, S. U., Ahmed, M. B., Ahsan, H., & Lee, Y. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_10 · Cited by 4

CAR-T cells : lymphocytes exprimant un récepteur chimérique à l’antigène

Chabannon, C., Bouabdallah, R., Fürst, S., Granata, A., Saillard, C., Vey, N., Mokart, D., Fougereau, E., Lemarié, C., Mfarrej, B. G., et al. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.12.002 · Cited by 3

Innate and adaptive immunity in cancer

Doshi, A. S., & Asrani, K. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00025-9 · Cited by 4

Eliciting a potent antitumor immune response by expressing tumor antigens in a skin commensalPreprint

Chen, Y. E., Atabakhsh, K., Dimas, A., Nagashima, K., & Fischbach, M. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.17.431662 · Cited by 3

TrambaHLApan: A Transformer and Mamba-based Neoantigen Prediction Method Considering both Antigen Presentation and Immunogenicity

Zhu, Y., Shi, X., Wang, L., & Zhang, J. (2025) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-025-00777-5 · Cited by 2

Biomarker-empowered precision navigation of CAR-T cell therapy

Wang, Y., Cheng, W., Kang, K., Niu, T., Zhao, A., & Wu, Y. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02647-0 · Cited by 5

Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports

Enzing, J. J., Knies, S., Engel, J., IJzerman, M. J., Sander, B., Vreman, R. A., Boer, B., & Brouwer, W. B. F. (2022) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-022-00383-y · Cited by 2

Aptamer-Based Chromatographic Methods for Efficient and Economical Separation of Leukocyte Populations

Ling, M., Cardle, I. I., Song, K., Yan, A. J., Kacherovsky, N. A., Jensen, M. C., & Pun, S. H. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00651 · Cited by 2

Clinicopathologic features of relapsed CD19 (−) B‐ALL in CD19 ‐targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B‐cell marker for CD19 (−) B lymphoblasts

Chen, D., Fuda, F. S., Rosado, F., Saumell, S., John, S., Chen, M., Koduru, P. R. K., & Chen, W. (2024) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14226 · Cited by 2

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy

Kalim, M., Jing, R., Li, X., Jiang, Z., Zheng, N., Wang, Z., Wei, G., & Lu, Y. (2024) · Journal of Cellular Immunology · doi:10.33696/immunology.6.189 · Cited by 2

Chimeric antigen-guiding extracellular vesicles eliminate antigen-specific Th2 cells in subjects with food allergy

Zhang, Y., Mo, L., Yang, G., Liu, J., Liu, Z., Yang, L., Ran, P., Liu, Z., & Yang, P. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100522 · Cited by 3

Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study

Zhai, Y., Hu, F., Zhu, B., Xu, J., Guo, X., Shi, W., Zhou, X., Zheng, Y., Xu, X., Ye, X., et al. (2023) · Immunotherapy · doi:10.2217/imt-2022-0145 · Cited by 2

Prise en charge des cellules CAR-T au sein des établis- sements de santé français : fabrication, distribution, et aspects réglementaires

Chabannon, C., & Larghero, J. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30209-2 · Cited by 2

The Evolution of Cancer Immunotherapy: A Journey from Concept to Clinical Reality

Mishra, A., & Malonia, S. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-88695-9_2 · Cited by 1

Deciphering the tumor microenvironment and role of immunotherapy in diffuse midline glioma: A scoping review

Ramsoomair, C. K., Sarmiento, F., Ramsoomair, D., Daftari, M., He, J., Glazer, B., Monje, M., Reinberg, D., & Shah, A. H. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag014 · Cited by 2

Rewriting CAR-T fate through cytokine engineering

Li, Y.-R., Yuen, T., Yeh, S., Clune, C. L., Dominguez-Vela, P., & Yang, L. (2026) · Trends Open · doi:10.1016/j.treopn.2026.05.004 · Cited by 1

Humoral immunity in cancer

Leonard, J., Duhamel, M., & Salzet, M. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02902-2 · Cited by 2

Chemical modification strategies of viral vectors for gene therapy

Zhang, C., & Zhou, D. (2018) · Scientia Sinica Chimica · doi:10.1360/n032018-00075

Stimuli-responsive drug delivery systems for cancer immunotherapy

Ding, Y., & Hu, Q. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824456-2.00014-x · Cited by 1

Potential clinical application of lncRNAs in pediatric cancer

Chhabra, R., Neyol, P., Bazala, S., Singh, I., Murmu, M., Sharma, U., Barwal, T. S., & Jain, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824550-7.00010-2 · Cited by 1

Rationing of Personalised Cancer Drugs: Rethinking the Co-production of Evidence and Priority Setting Practices

Tranvåg, E. J., & Strand, R. (2022) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-92612-0_14 · Cited by 1

FDA Approval of Tisagenlecleucel

Bach, P. B., Giralt, S. A., & Saltz, L. B. (2017) · JAMA · doi:10.1001/jama.2017.15218 · Cited by 168

Value and affordability of CAR T-cell therapy in the United States

Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J., & Roth, J. A. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0956-8 · Cited by 152

Improving outcomes and mitigating costs associated with CAR T-cell therapy

Rebecca Borgert, P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88737 · Cited by 87

The Value of CAR-T-cell Immunotherapy in Cancer

Abou‐El‐Enein, M., & Gauthier, J. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0_46 · Cited by 10

How Should We Determine the Value of CAR T-Cell Therapy?

Silbert, S. K., Yanik, G. A., & Shuman, A. G. (2019) · The AMA Journal of Ethic · doi:10.1001/amajethics.2019.844 · Cited by 20